01.02.2022 12:43:08
|
Bio-Techne Q2 Results Top Estimates; Declares Dividend - Quick Facts
(RTTNews) - Life sciences company Bio-Techne Corp. (TECH) reported Tuesday that second-quarter net earnings attributable to the company surged to $80.17 million or $1.94 per share from $46.27 million or $1.15 per share in the prior-year quarter.
Excluding items, adjusted earnings were $1.88 per share, compared to $1.62 per share in the year-ago quarter.
Net sales for the quarter increased 20 percent to $269.28 million from last year's $224.25 million. Organic revenue increased 17 percent, with acquisitions contributing 3 percent and foreign currency exchange having an immaterial impact.
On average, analysts polled by Thomson Reuters expected the company to report earnings of $1.79 per share on revenues of $266.57 million for the quarter. Analysts' estimates typically exclude special items.
Separately, Bio-Techne 's Board of Directors decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2021, payable on February 25, 2022 to all common shareholders of record on February 11, 2022.
The company also announced today that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $400 million of common stock. The new share repurchase program begins February 2, 2022 and replaces the previous program.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Techne Corpmehr Nachrichten
16:04 |
S&P 500-Papier Bio-Techne-Aktie: So viel hätte eine Investition in Bio-Techne von vor einem Jahr abgeworfen (finanzen.at) | |
14.11.24 |
S&P 500-Titel Bio-Techne-Aktie: So viel Gewinn hätte ein Bio-Techne-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
07.11.24 |
S&P 500-Titel Bio-Techne-Aktie: So viel hätten Anleger mit einem Investment in Bio-Techne von vor 5 Jahren verdient (finanzen.at) | |
31.10.24 |
S&P 500-Titel Bio-Techne-Aktie: So viel Verlust wäre bei einem Investment in Bio-Techne von vor 3 Jahren angefallen (finanzen.at) | |
30.10.24 |
Schwache Performance in New York: S&P 500 präsentiert sich zum Handelsende schwächer (finanzen.at) | |
30.10.24 |
S&P 500-Handel aktuell: So entwickelt sich der S&P 500 aktuell (finanzen.at) | |
30.10.24 |
Pluszeichen in New York: Börsianer lassen S&P 500 zum Start steigen (finanzen.at) | |
29.10.24 |
Ausblick: Bio-Techne stellt Zahlen zum jüngsten Quartal vor (finanzen.net) |